Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · page 39 of 50
The slide uses donut charts to represent remission rates and highlights the safety advantages of Spyre's gut-selective approach.
Deck · comparison_table · compare_peers · balanced density
Slide locked Sign in to view
Slide schematic 4/4
chart 1/1 disclaimer 1/1 table 1/1 title 1/1
Components 4
donut disclaimer data action-title
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1